OncoCyte Corporation
OCX
$2.94
-$0.22-6.96%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 178.08% | 25.15% | -51.54% | -7.08% | 57.94% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 178.08% | 25.15% | -51.54% | -7.08% | 57.94% |
| Cost of Revenue | 106.86% | 5.09% | -31.92% | -30.90% | -18.65% |
| Gross Profit | 290.49% | 65.27% | -80.41% | 318.67% | 424.85% |
| SG&A Expenses | 15.46% | 4.52% | -18.96% | -31.88% | -34.36% |
| Depreciation & Amortization | -17.05% | 0.00% | -1.12% | -1.12% | -2.22% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 16.93% | 5.71% | -4.41% | -14.44% | -17.85% |
| Operating Income | -6.72% | -4.40% | 1.44% | 14.76% | 20.28% |
| Income Before Tax | -45.72% | -144.07% | -106.63% | -122.96% | -332.28% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -45.72% | -144.07% | -106.63% | -122.96% | -332.28% |
| Earnings from Discontinued Operations | -- | -- | 100.00% | 100.00% | 100.00% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -45.72% | -118.36% | 24.00% | 39.37% | 32.96% |
| EBIT | -6.72% | -4.40% | 1.44% | 14.76% | 20.28% |
| EBITDA | -6.36% | -5.32% | -4.72% | 7.26% | 11.43% |
| EPS Basic | 28.62% | -24.71% | 51.93% | 57.34% | 52.42% |
| Normalized Basic EPS | 45.23% | 36.37% | 37.52% | 43.40% | 44.60% |
| EPS Diluted | 28.98% | -25.42% | 51.66% | 57.35% | 52.18% |
| Normalized Diluted EPS | 45.23% | 36.35% | 37.50% | 43.38% | 44.59% |
| Average Basic Shares Outstanding | 111.89% | 70.85% | 52.67% | 45.31% | 40.03% |
| Average Diluted Shares Outstanding | 111.89% | 70.83% | 52.64% | 45.28% | 40.01% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |